Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C13H16N2O2 |
Molecular Weight | 232.2783 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@]1(CCC(=O)NC1=O)C2=CC=C(N)C=C2
InChI
InChIKey=ROBVIMPUHSLWNV-CYBMUJFWSA-N
InChI=1S/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)/t13-/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1175729 | https://www.ncbi.nlm.nih.gov/pubmed/446416
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1175729 | https://www.ncbi.nlm.nih.gov/pubmed/446416
(R)-Aminoglutethimide is R-isomer of racemate anti-steroid drug Aminoglutethimide, marketed by Novartis for the treatment of Cushing syndrome and other conditions. (R)-Aminoglutethimide was shown to more active than (S)-isomer in inhibiting corticosteroid release in rats, more potent in inhibiting aromatization of testosterone by human placental microsomes. (R)-Aminoglutethimide was investigated in a clinical trial against breast cancer, where it was found to enhance the clearance rate of plasma estrone sulfate.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P11511 Gene ID: 1588.0 Gene Symbol: CYP19A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/446416 |
19.0 µM [IC50] | ||
Target ID: CHEMBL2033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1613747 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9709932
In a clinical trial against breast cancer, (R)-Aminoglutethimide was administered orally four times a day at doses 125 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/446416
To measure inhibition of placental aromatase, [1beta,2beta-3H]testosterone (107dpm) and 10 uM unlabeled testosterone was incubated with approximately 10 mg microsomal protein in 0.05 M sodium phosphate buffer (pH 7.4). Each tube was preincubated for 2 min at 25°C in a shaking water bath. The NADPH-generating system, consisting of 1 mM NADPH, 10 mM glucose-6-phosphate, and 1 U glucose-6-phosphate dehydrogenase, was added to start the reaction. Aminoglutethimide was added in 20 ul ethanol and an equal volume of ethanol was added to the control incubation tubes. Aliquots were withdrawn at 0, 5, 10, 15, and 20 min, and the reaction was terminated by the addition of 0.3 ml cold 1 mM HgCls and 1 ml 1% aqueous suspension of Norit A charcoal to each tube. After 20 min, the tubes were centrifuged to separate the charcoal-adsorbed steroids, and radioactivity associated with tritiated water was measured.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
86488
Created by
admin on Sat Dec 16 09:46:57 GMT 2023 , Edited by admin on Sat Dec 16 09:46:57 GMT 2023
|
PRIMARY | |||
|
LUC985IS6T
Created by
admin on Sat Dec 16 09:46:57 GMT 2023 , Edited by admin on Sat Dec 16 09:46:57 GMT 2023
|
PRIMARY | |||
|
55511-44-9
Created by
admin on Sat Dec 16 09:46:57 GMT 2023 , Edited by admin on Sat Dec 16 09:46:57 GMT 2023
|
PRIMARY | |||
|
DTXSID501318980
Created by
admin on Sat Dec 16 09:46:57 GMT 2023 , Edited by admin on Sat Dec 16 09:46:57 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD